The KCTD17 antibody is a tool used to detect the potassium channel tetramerization domain-containing 17 (KCTD17) protein, a member of the KCTD family implicated in diverse cellular processes. KCTD17 is characterized by an N-terminal BTB/POZ domain, which facilitates protein-protein interactions, and a C-terminal domain involved in substrate recognition. Studies suggest its role as an adaptor protein in cullin3-RING ubiquitin ligase complexes, regulating ubiquitination and degradation of target proteins. KCTD17 has been linked to neurodevelopmental processes, including Hedgehog signaling modulation, and its dysfunction is associated with neurological disorders such as epilepsy and autism spectrum disorders. Additionally, altered KCTD17 expression is observed in certain cancers, though its oncogenic or tumor-suppressive role remains context-dependent. The KCTD17 antibody is widely utilized in Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and interactions in both normal and pathological conditions. Its development and validation are critical for elucidating KCTD17's molecular mechanisms, particularly in neuronal development and disease pathogenesis. Commercial antibodies are typically raised against specific epitopes, with validation data confirming specificity through knockdown/knout experiments or peptide blocking assays. Ongoing research aims to clarify its therapeutic potential as a biomarker or drug target.